CTRI/2022/07/043981进行中(未招募)3 期
An Open Label, Prospective, Randomised, Non-Comparative, Two Arm Clinical Study to Evaluate the Effectiveness, Safety and Tolerability of â??Essen Plant Proteinâ?? of Essen Fooddies India Pvt. Ltd as a Nutritional Supplement in Physically Active Adults
Essen Fooddies India Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中(未招募)
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Clinically healthy Physically Active Adults between the ages of 40 and 65 years (both ages and all genders inclusive).
- •2.Subjects who are willing to abstain from use of herbal, allopathic or other nutritional supplements that are indicated at improving general health, strength and performance
- •3.Subjects who are not on rapid weight loss programs such as but not limited to keto, paleo, warrior, caveman diets. Intermittent fasting is permitted.
- •4.Subjects who have scored 12-14 in Mini Nutritional Assessment MNA-SF Questionnaire at the time of screening.
- •5.Subjects who are physically active i.e walk/cycle/perform other cardio activities for 30 minutes 3 times a week).
- •6.Subjects who are willing to give informed consent for participation, able to comprehend and understand the responsibilities during screening and treatment period.
- •7.Subjects who are willing not to participate in any other clinical trial during participation in the current trial.
排除标准
- •1.Subjects with known hypersensitivity to the ingredients of the investigational product
- •2.Subjects who have an active infection, disease or disorder that will prevent them from fully satisfying the responsibilities of the study.
- •3.Subjects with history of seizures, uncontrolled diabetes, hypertension or major cardiac illness like congestive heart failure etc.
- •4.Subjects on remission from cancer of any type less than 5 years at the time of screening
- •5.Subjects who are planning a pregnancy and/or currently breastfeeding.
- •6.Subjects who have participated in a clinical study less than 1 month before screening
- •7.Any significant medical condition (e.g., significant psychiatric or neurological disorders, active alcohol/drug abuse, etc.), any medical condition that is unstable/poorly controlled or other factor (e.g., planned relocation) that the Investigator felt would interfere with study evaluations and study participation.
- •8.Subjects who mentally unable to comprehend the responsibilities and adhere to the stipulations of the protocol.
- •9.Subjects, who in the opinion of the Investigator are not eligible for enrolment in the study.
研究者
相似试验
已完成
4 期
A clinical study to assess the safety of Imeglimin Tablets 500 mg in patients with diabetes.CTRI/2023/06/053621Exemed Pharmaceuticals210
已完成
4 期
A clinical study to assess the efficacy and safety of Imeglimin Tablets 1000 mg in patients with diabetes.CTRI/2023/02/050136Exemed Pharmaceuticals210
已完成
不适用
To Compare and Evaluate the Effect of Duchenne Muscular Dystrophy affected Patients Undergoing Current TreatmentAlong with Food SupplementsCTRI/2021/05/033346ichiIn Biosciences Pvt Ltd28
尚未招募
不适用
To Compare and Evaluate the Effect of Corona affected Patients Undergoing Current Treatment Along with Food SupplementsCTRI/2021/04/032766ichiIn Biosciences Pvt Ltd
尚未招募
3 期
Clinical Study on Nichi Glucan to Verify Effectiveness on Covid19CTRI/2021/10/037380ichiIn Bio Sciences Pvt Ltd
